-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On March 30, Kangfang Biological announced that the FDA granted Paimrizumab breakthrough therapy qualification for the third-line treatment of metastatic nasopharyngeal carcinoma.
Kangfang Bio-Bio announced in September 2020 that the registered clinical trial of Paimrizumab for the third-line treatment of metastatic nasopharyngeal carcinoma has reached the primary endpoint of objective response rate (ORR) assessed by independent imaging, and has undergone multi-line treatment in the past.
Nasopharyngeal carcinoma is a malignant tumor that occurs in the mucosal epithelium of the nasopharyngeal area, and mostly occurs in the top and side walls of the nasopharynx.
Pianprizumab was jointly developed and commercialized by Kangfang Biotechnology and Chia Tai Tianqing.
In May 2020, Kangfang Bio-Bio submitted to NMPA a new drug listing application for Paimrizumab to treat relapsed or refractory classic Hodgkin's lymphoma (r/rcHL) after at least second-line system chemotherapy.
